Martingale Asset Management L P Decreases Stock Position in Abbott Laboratories $ABT

Martingale Asset Management L P cut its holdings in Abbott Laboratories (NYSE:ABT) by 11.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 210,116 shares of the healthcare product maker’s stock after selling 27,920 shares during the period. Martingale Asset Management L P’s holdings in Abbott Laboratories were worth $28,143,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new position in shares of Abbott Laboratories during the second quarter valued at $3,026,180,000. Laurel Wealth Advisors LLC boosted its position in shares of Abbott Laboratories by 13,347.0% during the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after buying an additional 6,011,891 shares during the last quarter. Invesco Ltd. increased its holdings in Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Vanguard Group Inc. raised its position in Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in Abbott Laboratories by 180.7% during the 2nd quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after acquiring an additional 1,972,097 shares during the period. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ABT. The Goldman Sachs Group reduced their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Daiwa Securities Group lowered their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Argus dropped their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Oppenheimer decreased their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, Evercore lowered their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Insider Buying and Selling

In related news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This trade represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 3,055 shares of company stock worth $353,097 in the last quarter. Company insiders own 0.46% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New clinical evidence — The FreeDM2 randomized trial showed FreeStyle Libre continuous glucose monitoring produced meaningful improvements in HbA1c and more time-in-range for people with Type 2 diabetes on basal insulin, supporting adoption and longer-term revenue upside for Abbott’s diabetes business. Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
• Positive Sentiment: Brand/consumer engagement — Abbott relaunched its “Abbott Dream Team” program with Real Madrid, a marketing push that can boost awareness for consumer-facing segments (nutrition, diagnostics) and strengthen long-term end-market demand. Abbott and Real Madrid launch nationwide effort to build the next ‘Abbott Dream Team’
• Positive Sentiment: Value narrative — Analyst commentary and stock-screen mentions (Zacks, dividend-aristocrat lists) emphasize ABT’s defensive characteristics, dividend safety and long-term value, which can support investor demand despite near-term noise. Why Abbott (ABT) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Analyst views diverging — Coverage shows only small shifts in modeled fair value overall, but several analysts are revising targets and re-weighting execution risk vs. long-run growth; this creates mixed signals and short-term volatility. How The Story On Abbott Laboratories (ABT) Is Shifting As Analysts Rework Targets And Risks
• Negative Sentiment: Near-term earnings reception — Q4 revenue came in below consensus while EPS roughly met estimates, and sector Q4 comparisons flagged pockets of weakness; that revenue miss likely pressured the stock. Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies – Diversified Stocks
• Negative Sentiment: Price-target actions — Citigroup trimmed its price target slightly (from $140 to $136) while keeping a buy rating; small cuts across some desks add downward pressure even if sentiment remains constructive. Benzinga: Citigroup price target cut

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $108.18 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $187.98 billion, a PE ratio of 29.08, a price-to-earnings-growth ratio of 1.75 and a beta of 0.74. The firm’s 50 day moving average price is $114.91 and its 200-day moving average price is $124.08. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same period in the previous year, the business posted $1.34 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.